MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


IN BRIEF: PureTech’s LYT-100 shows 50% improvement to key adverse events

ALN

PureTech Health PLC - Boston-based biotechnology company - Says LYT-100 trial shows around 50% improvement in gastrointestinal and central nervous system related adverse events in adults suffering from idiopathic pulmonary fibrosis compared to US Food & Drug Administration-approved pirfenidone. Adds data shows higher dose of LYT-100 well-tolerated with no additional incidence of GI or CNS AEs when titrated up from 550 milligrams dosage.

Chief Medical Officer Julie Krop says: ‘These data highlight the potential for LYT-100 to improve both the treatment experience for people with IPF and - most importantly - enable them to stay on treatment longer and at an efficacious dose, which should improve their clinical outcome. Our goal with the ELEVATE IPF trial is to validate the ability of LYT-100 to deliver a more tolerable treatment with equivalent efficacy to pirfenidone at one dose while also exploring the potential for enhanced efficacy at a higher dose.’

Current stock price: 185.20 pence, down 0.9% in London on Wednesday afternoon

12-month change: down 14%

Copyright 2023 Alliance News Ltd. All Rights Reserved.